Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Lazic, Aleksandar (57394252100)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Adenocarcinoma of the duodenojejunal flexure: our recent experience
    (2023)
    Mitrovic, Nebojsa (56235199600)
    ;
    Stevanovic, Dejan (57461284600)
    ;
    Jasarovic, Damir (26023271400)
    ;
    Lazic, Aleksandar (57394252100)
    Background: Duodenal adenocarcinomas account for 0.3% of all gastrointestinal malignancies. Most of them are found in the second portion of the duodenum, while those in the third and/or fourth portions, particularly at the duodenojejunal flexure, are very rare, representing a separate entity. Case presentation: We had two male patients who presented with non-specific symptoms in the form of pain in the upper abdomen accompanied by nausea and vomiting. After CT diagnostics had revealed duodenal lesions in the region of the Treitz ligament, patients were subjected to operative treatment, with curative intent in the first case and palliative intent in the second case due to peritoneal carcinomatosis. Conclusion: The insidious onset and vague abdominal symptoms, even when the disease has progressed, coupled with the difficulty of viewing this location and performing a biopsy, make diagnosing these neoplasms particularly difficult. The only possible curative option is surgical resection. A higher degree of suspicion and a more aggressive and persistent investigation should lead to earlier treatment, a higher curative resectability rate, and therefore better long-term results. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Analysis of Lower Extremity Amputations from the SerbVasc Registry
    (2023)
    Tanaskovic, Slobodan (25121572000)
    ;
    Ilijevski, Nenad (57209017323)
    ;
    Koncar, Igor (19337386500)
    ;
    Matejevic, David (57657574700)
    ;
    Popovic, Miroslava (58611962900)
    ;
    Stefanovic, Zvezdan (35085639500)
    ;
    Babic, Aleksandar (57340398100)
    ;
    Lazic, Aleksandar (57394252100)
    ;
    Knezevic, Dragan (57201430785)
    ;
    Damnjanovic, Zoran (19433895100)
    ;
    Pesic, Slobodan (58525670300)
    ;
    Stankovic, Jelena (58561379800)
    ;
    Marjanovic, Ivan (36928024700)
    ;
    Davidovic, Lazar (7006821504)
    Background: Peripheral arterial disease (PAD) and diabetes are the major causes of lower extremity amputations (LEAs) worldwide. Morbidity and mortality in patients with LEAs are high with an associated significant burden on the global health system. The aim of this article is to report the overall morbidity and mortality rates after major and minor LEAs from the Serbian Vascular Registry (SerbVasc), with an analysis of predictive factors that influenced adverse outcomes. Materials and methods: SerbVasc was created in 2019 as a part of the Vascunet collaboration that is aiming to include all vascular procedures from 21 hospitals in Serbia. Prevalence of diabetes among patients with LEAs, previous revascularization procedures, the degree and the type of foot infection and tissue loss, and overall morbidity and mortality rates were analyzed, with a special reference to mortality predictors. Results: In the period from January 2020 to December 2022, data on 702 patients with LEAs were extracted from the SerbVasc registry, mean age of 69.06±10.63 years. Major LEAs were performed in 59%, while minor LEAs in 41% of patients. Diabetes was seen in 65.1% of the patients, with 44% of them being on insulin therapy. Before LEA, only 20.3% of patients had previous peripheral revascularization. Soft tissue infection, irreversible acute ischemia, and Fontaine III and IV grade ischemia were the most common causes of above-the-knee amputations while diabetic foot was the most common cause of transphalangeal and toe amputations. The infection rate was 3.7%, the re-amputation rate was 5.7%, and the overall mortality rate was 6.9%, with intrahospital mortality in patients with above-the-knee amputation of 11.1%. The most significant intrahospital mortality predictors were age >65 years (p<0.001), chronic kidney disease (CKD) (p<0.001), ischemic heart disease (IHD) (p=0.001), previous myocardial revascularization (p=0.017), emergency type of admission (p<0.001), not using aspirin (p=0.041), using previous anticoagulation therapy (p=0.003), and postoperative complications (p<0.001). Conclusions: The main predictors of increased mortality after LEAs from the SerbVasc registry are age >65 years, CKD, IHD, previous myocardial revascularization, emergency type of admission, not using aspirin, using previous anticoagulation therapy, and postoperative complications. Taking into account high mortality rates after LEAs and a small proportion of previous peripheral revascularization, the work should be done on early diagnosis and timely treatment of PAD hopefully leading to decreased number of LEAs and overall mortality. Clinical Impact: Mortality after lower limb amputation from the SerbVasc register is high. A small number of previously revascularized patients is of particular clinical importance, bearing in mind that the main reasons for above-the-knee amputations were irreversible ischemia, Fontaine III and Fontaine IV grade ischemia. Lack of diagnostics procedures and late recognition of patients with PAD, led to subsequent threating limb ischemia and increased amputation rates. The work should be done on early diagnosis and timely treatment of PAD in Serbia, hopefully leading to an increased number of PAD procedures, decreased number of LEAs, and lower overall mortality. © The Author(s) 2023.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback